H. Lundbeck A/S and our business partners use cookies to make the website function, for traffic measurement, optimization of content of the website and targeting marketing. By using our website you agree to the use of cookies for these purposes. You can read more about cookies, including how to disable them, in our cookie policy. You have the right to withdraw your consent at any time. However, if you withdraw your consent, it will not affect the processing of your personal data prior to the withdrawal of your consent. By clicking “Accept cookies”, you accept the use of cookies.
Our Research and Development (R&D) efforts are dedicated to creating new and innovative pharmaceuticals for the treatment of psychiatric and neurological disorders. Through investment and perseverance, we strive to create the very best treatments for patients.
We are the only fully-integrated pharmaceutical company in the world, solely devoted to the treatment of psychiatric and neurological disorders. We dedicate our entire R&D efforts to develop innovative drugs for treatment of a number of psychiatric and neurological disorders. Our R&D projects focus on: Alzheimer’s disease, Depression, Parkinson’s disease, and Schizophrenia.
Send me alerts every days
alert frequency on certain days
Save Category as RSS Feed
Results 1 – 6 of 6Page 1 of 1
Search results for
"".
Page 1 of 1, Results 1 to 6
